

Deliver the outcomes
that matter to your patients

■ euro
PCR



Symposium

Complex patients: optimal combination of stents and adjunctive therapy

Wednesday May 16, 2012

12:00-13:30h

Theatre Havane (Level 3)

Chairpersons:

Alexandre Abizaid, Philip Urban

OBJECTIVES

- To understand how DES technology can impact patient selection and clinical outcome
- To evaluate the clinical implication of dual antiplatelet therapy duration and strategy based on patient selection
- To understand why trial design is important to address unmet needs
- To be updated on the design of future trials

12:00 • Philip Urban

Introduction and objectives

12:05 • Renu Virmani

DES - Technology evolution: where are we today?

12:20 • Stephan Windecker

The impact of patient and lesion complexity on clinical outcomes

12:35 • Marco Valgimigli

Can dual antiplatelet therapy be discontinued with any stent in any patient at any time?

12:50 • Philip Urban and Stephan Windecker

Taking the LEAD in clinical excellence: revolutionary trial designs will bring the answer

- LEADERS FREE
- GLOBAL LEADERS

13:10 • All

Discussion

13:20 • Alexandre Abizaid

Take-home message

Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and other countries.
Not available for sale in the United States and certain other countries.
© 2012. Biosensors International Group, Ltd. All rights reserved.